



Active substances set

Search phrase: brexucabtagene autoleucel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Brexucabtagene autoleucel

Mantle cell lymphoma Brexucabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO

Acute lymphoid leukemia

Brexucabtagene autoleucel

Acute lymphoblastic leukaemia Brexucabtagene autoleucel is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).



NO REIMBURSEMENT



ESMO